73568-25-9 2-氯-3-喹啉甲醛

运输信息：常温运输。危险描述：危险性质为否，属于非危险品。

化学合成

化学合成

路线1：以乙酰苯胺、BTC和DMF为原料

• 步骤：冰盐浴下，向2.73g（20.22mmol）乙酰苯胺、8.19g（27.58mmol）BTC和10mL三氯甲烷的混合物中，30分钟内滴加4.2mL（54.66mmol）DMF，控制温度低于-5℃；滴加完毕搅拌10分钟，水浴加热至40℃反应4小时；蒸去部分溶剂，加入冰水，用10%NaOH调节pH至8~9，抽滤，乙酸乙酯重结晶。
• 条件：以双（三氯甲基）碳酸酯（BTC）为试剂，三氯甲烷为溶剂，反应温度-5~40℃，总反应时间约4.67小时，绿色化学工艺。
• 收率：91.62%
• 参考文献：[1] Patent: CN106831566, 2017, A. Location in patent: Paragraph 0005; 0022-0033 [2] Tetrahedron Letters, 1997, vol. 38, # 28, p. 4969 - 4972 [3] Synlett, 2001, # 2, p. 251 - 253 [4] Journal of Photochemistry and Photobiology B: Biology, 2016, vol. 165, p. 266 - 276 [5] Journal of the Brazilian Chemical Society, 2014, vol. 25, # 2, p. 365 - 371 [6] Journal of the Brazilian Chemical Society, 2014, vol. 25, # 7, p. 1253 - 1260 [7] Research on Chemical Intermediates, 2015, vol. 41, # 8, p. 5379 - 5388 [8] Asian Journal of Chemistry, 2015, vol. 27, # 10, p. 3667 - 3670 [9] Medicinal Chemistry Research, 2013, vol. 22, # 2, p. 635 - 646 [10] Medicinal Chemistry Research, 2013, vol. 22, # 2, p. 647 - 658 [11] Journal of Organometallic Chemistry, 2015, vol. 798, p. 125 - 131 [12] Synthetic Communications, 2002, vol. 32, # 9, p. 1351 - 1356 [13] Letters in Organic Chemistry, 2011, vol. 8, # 1, p. 53 - 59 [14] Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 2005, vol. 44, # 9, p. 1868 - 1875 [15] Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 2006, vol. 45, # 1, p. 292 - 296 [16] Journal of Molecular Structure, 2014, vol. 1070, # 1, p. 10 - 20 [17] Synlett, 2006, # 16, p. 2593 - 2596 [18] Tetrahedron, 2009, vol. 65, # 34, p. 7099 - 7104 [19] Journal of Sulfur Chemistry, 2011, vol. 32, # 5, p. 475 - 481 [20] Chinese Journal of Chemistry, 2016, vol. 34, # 4, p. 403 - 411 [21] Synlett, 2000, # 8, p. 1115 - 1118 [22] Oriental Journal of Chemistry, 2016, vol. 32, # 4, p. 1977 - 1982 [23] Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999), 1981, p. 1520 - 1530 [24] Tetrahedron Letters, 2008, vol. 49, # 17, p. 2810 - 2814 [25] Synthetic Communications, 2016, vol. 46, # 3, p. 287 - 291 [26] Patent: WO2017/83979, 2017, A1. Location in patent: Paragraph 00117; 00119; 00122 [27] Chemistry of Heterocyclic Compounds, 2017, vol. 53, # 4, p. 434 - 445 [28] Khim. Geterotsikl. Soedin., 2017, vol. 53, # 4, p. 434 - 445,12 [29] Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 2002, vol. 41, # 2, p. 433 - 435 [30] Patent: WO2006/73973, 2006, A2. Location in patent: Page/Page column 197-198 [31] Journal of Physical Organic Chemistry, 2011, vol. 24, # 3, p. 203 - 211 [32] Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 2011, vol. 50, # 10, p. 1491 - 1495 [33] Journal of the Brazilian Chemical Society, 2011, vol. 22, # 9, p. 1742 - 1749 [34] Synlett, 2011, # 1, p. 84 - 88 [35] Medicinal Chemistry Research, 2014, vol. 24, # 6, p. 2514 - 2528 [36] Bioorganic Chemistry, 2018, vol. 80, p. 591 - 601 [37] Bioorganic and Medicinal Chemistry, 2015, vol. 23, # 3, p. 602 - 611 [38] Synthetic Communications, 2006, vol. 36, # 23, p. 3581 - 3589 [39] Molecules, 2016, vol. 21, # 7, [40] Archiv der Pharmazie, 2006, vol. 339, # 5, p. 242 - 249 [41] Patent: WO2015/51149, 2015, A1. Location in patent: Paragraph 0091; 0092 [42] Synthetic Communications, 2004, vol. 34, # 11, p. 2019 - 2024 [43] Synthetic Communications, 2005, vol. 35, # 21, p. 2779 - 2788 [44] Tetrahedron Letters, 2006, vol. 47, # 44, p. 7779 - 7782 [45] Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 2007, vol. 46, # 2, p. 303 - 307 [46] Synlett, 2007, # 12, p. 1873 - 1876 [47] Phosphorus, Sulfur and Silicon and the Related Elements, 2008, vol. 183, # 8, p. 1870 - 1883 [48] Chemical and Pharmaceutical Bulletin, 2009, vol. 57, # 6, p. 557 - 560 [49] Synthesis, 2010, # 18, p. 3179 - 3187 [50] Bioorganic and Medicinal Chemistry Letters, 2010, vol. 20, # 19, p. 5718 - 5721 [51] European Journal of Medicinal Chemistry, 2009, vol. 44, # 11, p. 4477 - 4484 [52] Journal of Heterocyclic Chemistry, 2010, vol. 47, # 1, p. 81 - 84 [53] Inorganic Chemistry Communications, 2010, vol. 13, # 5, p. 606 - 608 [54] European Journal of Medicinal Chemistry, 2010, vol. 45, # 11, p. 5353 - 5361 [55] European Journal of Medicinal Chemistry, 2011, vol. 46, # 5, p. 1897 - 1905 [56] Acta Poloniae Pharmaceutica - Drug Research, 2010, vol. 67, # 5, p. 567 - 573 [57] Organic Process Research and Development, 2010, vol. 14, # 6, p. 1490 - 1500 [58] Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 2011, vol. 50, # 9, p. 1202 - 1207 [59] Heterocyclic Communications, 2011, vol. 17, # 3-4, p. 111 - 119 [60] Dalton Transactions, 2011, vol. 40, # 37, p. 9370 - 9373 [61] E-Journal of Chemistry, 2010, vol. 7, # 4, p. 1196 - 1199 [62] Transition Metal Chemistry, 2011, vol. 36, # 5, p. 489 - 498 [63] Chinese Chemical Letters, 2012, vol. 23, # 3, p. 273 - 276 [64] Journal of the Serbian Chemical Society, 2012, vol. 77, # 3, p. 279 - 286 [65] Chinese Chemical Letters, 2012, vol. 23, # 4, p. 454 - 457 [66] Journal of Heterocyclic Chemistry, 2012, vol. 49, # 1, p. 80 - 87 [67] Journal of Chemical Sciences, 2011, vol. 123, # 5, p. 645 - 655 [68] Bioorganic and Medicinal Chemistry Letters, 2012, vol. 22, # 11, p. 3816 - 3821 [69] Medicinal Chemistry Research, 2012, vol. 21, # 7, p. 1188 - 1198 [70] Journal of Chemical Sciences, 2012, vol. 124, # 3, p. 669 - 677 [71] European Journal of Medicinal Chemistry, 2012, vol. 54, p. 239 - 247 [72] Bioorganic and Medicinal Chemistry Letters, 2013, vol. 23, # 1, p. 107 - 111 [73] Chinese Chemical Letters, 2012, vol. 23, # 12, p. 1367 - 1370 [74] Indian Journal of Heterocyclic Chemistry, 2011, vol. 21, # 1, p. 69 - 72 [75] Research on Chemical Intermediates, 2018, vol. 44, # 4, p. 2439 - 2449 [76] RSC Advances, 2018, vol. 8, # 43, p. 24376 - 24385 [77] Tetrahedron, 2013, vol. 69, # 10, p. 2309 - 2318 [78] Tetrahedron, 2013, vol. 69, # 16, p. 3451 - 3458 [79] Journal of Chemical Sciences, 2013, vol. 125, # 2, p. 321 - 333 [80] Journal of the Serbian Chemical Society, 2013, vol. 78, # 5, p. 621 - 625 [81] Tetrahedron, 2013, vol. 69, # 41, p. 8668 - 8674 [82] Medicinal Chemistry Research, 2014, vol. 23, # 1, p. 42 - 56 [83] Tetrahedron Letters, 2014, vol. 55, # 31, p. 4395 - 4399 [84] European Journal of Medicinal Chemistry, 2014, vol. 83, p. 569 - 580 [85] Chinese Chemical Letters, 2014, vol. 25, # 7, p. 1073 - 1076 [86] Journal of Chemical Sciences, 2014, vol. 126, # 1, p. 205 - 212 [87] Journal of Sulfur Chemistry, 2018, vol. 39, # 4, p. 435 - 442 [88] Letters in Drug Design and Discovery, 2013, vol. 10, # 1, p. 75 - 85 [89] Letters in Organic Chemistry, 2014, vol. 11, # 10, p. 736 - 742 [90] Asian Journal of Chemistry, 2014, vol. 26, # 21, p. 7449 - 7451 [91] Chemical Communications, 2015, vol. 51, # 44, p. 9125 - 9128 [92] Journal of the Iranian Chemical Society, 2015, vol. 12, # 8, p. 1313 - 1324 [93] Journal of the Iranian Chemical Society, 2015, vol. 12, # 9, p. 1577 - 1584 [94] Journal of Enzyme Inhibition and Medicinal Chemistry, 2016, vol. 31, p. 205 - 209 [95] Journal of Agricultural and Food Chemistry, 2015, vol. 63, # 23, p. 5587 - 5596 [96] Bulletin of the Korean Chemical Society, 2015, vol. 36, # 2, p. 719 - 722 [97] Bioorganic and Medicinal Chemistry Letters, 2015, vol. 25, # 17, p. 3601 - 3605 [98] Organic and Biomolecular Chemistry, 2015, vol. 13, # 30, p. 8211 - 8220 [99] Research on Chemical Intermediates, 2015, vol. 41, # 8, p. 5509 - 5519 [100] Medicinal Chemistry Research, 2015, vol. 24, # 11, p. 3892 - 3911 [101] Research on Chemical Intermediates, 2015, vol. 41, # 11, p. 8381 - 8403 [102] Bioorganic and Medicinal Chemistry, 2015, vol. 23, # 24, p. 7629 - 7640 [103] Bioorganic and Medicinal Chemistry Letters, 2016, vol. 26, # 9, p. 2278 - 2283 [104] Synthesis (Germany), 2016, vol. 48, # 14, p. 2178 - 2190 [105] Bioorganic and Medicinal Chemistry Letters, 2016, vol. 26, # 7, p. 1696 - 1703 [106] European Journal of Medicinal Chemistry, 2017, vol. 141, p. 567 - 583 [107] Bioorganic and Medicinal Chemistry Letters, 2018, vol. 28, # 13, p. 2244 - 2249 [108] European Journal of Medicinal Chemistry, 2018, vol. 157, p. 139 - 150 [109] MedChemComm, 2016, vol. 7, # 9, p. 1832 - 1848 [110] European Journal of Inorganic Chemistry, 2016, vol. 2016, # 26, p. 4199 - 4206 [111] Synthetic Communications, 2017, vol. 47, # 3, p. 224 - 231 [112] Medicinal Chemistry Research, 2017, vol. 26, # 1, p. 109 - 119 [113] Journal of Heterocyclic Chemistry, 2017, vol. 54, # 1, p. 102 - 109 [114] Letters in Drug Design and Discovery, 2018, vol. 15, # 9, p. 914 - 922 [115] Dalton Transactions, 2017, vol. 46, # 15, p. 5069 - 5075 [116] Journal of Molecular Structure, 2017, vol. 1149, p. 439 - 451 [117] Journal of Heterocyclic Chemistry, 2017, vol. 54, # 5, p. 2740 - 2747 [118] Synthetic Communications, 2017, vol. 47, # 20, p. 1884 - 1904 [119] Research on Chemical Intermediates, 2017, vol. 43, # 11, p. 6131 - 6154

路线2：以2-氯喹啉、二异丙胺和n-BuLi为原料

• 步骤：0℃下，向0.46mL（3.30mmol）二异丙胺的8mL THF溶液中滴加1.53mL（3.30mmol）n-BuLi，搅拌20分钟；冷却至-78℃，加入2-氯喹啉（491mg，3.0mmol），搅拌30分钟；滴加二甲基甲酰胺（0.39mL，5.04mmol），继续搅拌30分钟；-78℃下用1mL冰醋酸淬灭，升温至室温，乙醚稀释；有机相用饱和NaHCO₃溶液和盐水洗涤，MgSO₄干燥，浓缩得产物。
• 条件：以n-丁基锂、二异丙胺为试剂，四氢呋喃为溶剂，反应温度-78~0℃。
• 收率：92%
• 产物性质：浅黄色固体，熔点145°-149℃，可直接用于下一步反应；乙酸乙酯重结晶后为淡黄色针状物，熔点149-150℃。
• 表征：¹H NMR（300MHz，CDCl₃）δ10.57（s，1H），8.77（s，1H），8.08（d，1H，J=9Hz），8.0（d，1H，J=9Hz），7.90（t，1H，J=9Hz），7.67（t，1H，J=9Hz）；IR（nujol）1685,1575,1045,760,745cm⁻¹。
• 参考文献：[1] Patent: US5212317, 1993, A [2] Patent: US5162532, 1992, A

路线3：以乙酰苯胺、三氯氧磷和DMF为原料

• 步骤：将24.0mL（260mmol）三氯氧磷滴加到冰冷的7.20mL（93.0mmol）二甲基甲酰胺溶液中，0℃搅拌30分钟；加入乙酰苯胺（5.0g，37.0mmol），0℃搅拌30分钟后，75℃加热16小时；冷却后倒入250mL冰水，0°-5℃搅拌30分钟；过滤，水洗，乙酸乙酯重结晶得产物。
• 条件：以三氯氧磷为试剂，反应温度0~75℃。
• 收率：74%
• 产物性质：浅黄色固体，熔点147°-149℃。
• 参考文献：[1] Patent: US5212317, 1993, A [2] Patent: US5162532, 1992, A [3] Patent: US4735948, 1988, A [4] Patent: US4496569, 1985, A [5] Journal of Chemical Sciences, 2014, vol. 126, # 1, p. 205 - 212